Hematologic Malignancy
Indolent Systemic Mastocytosis
CI-CAN-00007849ISMExplore in graph →
HematologicNon-malignant3 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007849ISMExplore in graph →
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT07264959 | An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) | recruiting | — | 150 | Blueprint Medicines CorporationINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06210698 | Angioedema Biomarker Research Study | recruiting | — | 600 | Foundation For Rare Disease ResearchOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07255638 |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials
| recruiting |
| — |
| 80 |
| Blueprint Medicines CorporationINDUSTRY |
| 1 |
| Apr 20, 2026 |
| clinicaltrials |